203 related articles for article (PubMed ID: 12717846)
21. Deep sequencing of hepatitis C virus hypervariable region 1 reveals no correlation between genetic heterogeneity and antiviral treatment outcome.
Cortés KC; Zagordi O; Perlejewski K; Laskus T; Maroszek K; Bukowska-Ośko I; Pawełczyk A; Płoski R; Berak H; Horban A; Radkowski M
BMC Infect Dis; 2014 Jul; 14():389. PubMed ID: 25016390
[TBL] [Abstract][Full Text] [Related]
22. Antibody responses against B-cell epitopes of the hypervariable region 1 of hepatitis C virus in self-limiting and chronic human hepatitis C followed-up using consensus peptides.
Isaguliants MG; Widell A; Zhang SM; Sidorchuk A; Levi M; Smirnov VD; Santantonio T; Diepolder HM; Pape GR; Nordenfelt E
J Med Virol; 2002 Feb; 66(2):204-17. PubMed ID: 11782929
[TBL] [Abstract][Full Text] [Related]
23. Antibody-free virion titer greatly differs between hepatitis C virus genotypes.
Kimura Y; Hayashida K; Ishibashi H; Niho Y; Yanagi Y
J Med Virol; 2000 May; 61(1):37-43. PubMed ID: 10745230
[TBL] [Abstract][Full Text] [Related]
24. Human recombinant single-chain antibody fragments, specific for the hypervariable region 1 of hepatitis C virus, from immune phage-display libraries.
Zhai W; Davies J; Shang DZ; Chan SW; Allain JP
J Viral Hepat; 1999 Mar; 6(2):115-24. PubMed ID: 10607222
[TBL] [Abstract][Full Text] [Related]
25. Hypervariable region diversity of hepatitis C virus and humoral response: comparison between patients with or without cirrhosis.
Allain JP; Zhai W; Shang D; Timmers E; Alexander GJ
J Med Virol; 1999 Sep; 59(1):25-31. PubMed ID: 10440804
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of the immunogenicity of liposome encapsulated HVR1 and NS3 regions of genotype 3 HCV, either singly or in combination.
Gupte GM; Arankalle VA
Virol J; 2012 Mar; 9():74. PubMed ID: 22452828
[TBL] [Abstract][Full Text] [Related]
27. Reproduction in vitro of a quasispecies from a hepatitis C virus-infected patient and determination of factors that influence selection of a dominant species.
Kawaguchi K; Faulk K; Purcell RH; Emerson SU
J Virol; 2011 Apr; 85(7):3408-14. PubMed ID: 21270157
[TBL] [Abstract][Full Text] [Related]
28. Characterization of antibody-mediated neutralization directed against the hypervariable region 1 of hepatitis C virus E2 glycoprotein.
Vieyres G; Dubuisson J; Patel AH
J Gen Virol; 2011 Mar; 92(Pt 3):494-506. PubMed ID: 21084495
[TBL] [Abstract][Full Text] [Related]
29. Expression of Hepatitis C Virus Core and E2 antigenic recombinant proteins and their use for development of diagnostic assays.
Ali A; Nisar M; Idrees M; Rafique S; Iqbal M
Int J Infect Dis; 2015 May; 34():84-9. PubMed ID: 25796431
[TBL] [Abstract][Full Text] [Related]
30. Immunizations with chimeric hepatitis B virus-like particles to induce potential anti-hepatitis C virus neutralizing antibodies.
Vietheer PT; Boo I; Drummer HE; Netter HJ
Antivir Ther; 2007; 12(4):477-87. PubMed ID: 17668556
[TBL] [Abstract][Full Text] [Related]
31. Multigene tracking of quasispecies in viral persistence and clearance of hepatitis C virus.
Chen S; Wang YM
World J Gastroenterol; 2005 May; 11(19):2874-84. PubMed ID: 15902722
[TBL] [Abstract][Full Text] [Related]
32. Evolution of hepatitis C virus hypervariable region 1 in chronically infected children.
Jackowiak P; Kowala-Piaskowska A; Figlerowicz M; Alejska M; Malinowska N; Figlerowicz M
Virus Res; 2012 Aug; 167(2):380-4. PubMed ID: 22610132
[TBL] [Abstract][Full Text] [Related]
33. Insertion and recombination events at hypervariable region 1 over 9.6 years of hepatitis C virus chronic infection.
Palmer BA; Moreau I; Levis J; Harty C; Crosbie O; Kenny-Walsh E; Fanning LJ
J Gen Virol; 2012 Dec; 93(Pt 12):2614-2624. PubMed ID: 22971825
[TBL] [Abstract][Full Text] [Related]
34. Genetic complexity and serum reactivity of HVR1 quasispecies of hepatitis C virus in patients with cirrhosis.
Fan X; Di Bisceglie AM
Am J Gastroenterol; 2002 Jun; 97(6):1489-95. PubMed ID: 12094871
[TBL] [Abstract][Full Text] [Related]
35. Expression, purification, immunological characterization and application of Escherichia coli-derived hepatitis C virus E2 proteins.
Liu J; Zhu L; Zhang X; Lu M; Kong Y; Wang Y; Li G
Biotechnol Appl Biochem; 2001 Oct; 34(2):109-19. PubMed ID: 11592917
[TBL] [Abstract][Full Text] [Related]
36. Humoral immune system targets clonotypic antibody-associated hepatitis C virus.
Naik AS; Palmer BA; Crosbie O; Kenny-Walsh E; Fanning LJ
J Gen Virol; 2017 Feb; 98(2):179-189. PubMed ID: 28284234
[TBL] [Abstract][Full Text] [Related]
37. Sequence evolution and cross-reactive antibody responses to hypervariable region 1 in acute hepatitis C virus infection.
Hjalmarsson S; Blomberg J; Grillner L; Pipkorn R; Allander T
J Med Virol; 2001 Jun; 64(2):117-24. PubMed ID: 11360243
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of cross-reactive antibody response to HVR1 in chronic hepatitis C.
Xiu BS; Feng XY; He J; Wang GH; Zhang XY; Zhang HQ; Song XG; Chen K; Ling SG; Zhu CX; Wei L; Rao HY
World J Gastroenterol; 2010 Sep; 16(35):4460-6. PubMed ID: 20845515
[TBL] [Abstract][Full Text] [Related]
39. Characterization of antibody response to hepatitis C virus protein E2 and significance of hypervariable region 1-specific antibodies in viral neutralization.
Zibert A; Dudziak P; Schreier E; Roggendorf M
Arch Virol; 1997; 142(3):523-34. PubMed ID: 9349298
[TBL] [Abstract][Full Text] [Related]
40. Influence of viral load and alanine aminotransferase on viral genetic heterogeneity in patients with chronic hepatitis C virus infection.
Bozdayi AM; Uzunalimoglu O; Aslan N; Bozkaya H; Türkyilmaz AR; Kayhan B; Sahin T; Sivri B; Uygun A; Altiok A; Cetinkaya H; Karayalçin S; Yurdaydin C
Intervirology; 2000; 43(1):61-6. PubMed ID: 10773739
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
